Intercept Pharma (ICPT) Tops Q2 EPS by 37c

Intercept Pharma (NASDAQ: ICPT) reported Q2 EPS of ($0.14), $0.37 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $83.72 million versus the consensus estimate of $79.57 million.

Company updates full-year 2023 Ocaliva net sales guidance to $320 million to $340 million; reiterates non-GAAP adjusted operating expense guidance of $350 million to $370 million.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15